ZIPAN-25 Drug Patent Profile
✉ Email this page to a colleague
When do Zipan-25 patents expire, and when can generic versions of Zipan-25 launch?
Zipan-25 is a drug marketed by Altana and is included in one NDA.
The generic ingredient in ZIPAN-25 is promethazine hydrochloride. There are twelve drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the promethazine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zipan-25
A generic version of ZIPAN-25 was approved as promethazine hydrochloride by ZYDUS PHARMS USA on November 18th, 2005.
Summary for ZIPAN-25
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 123 |
Patent Applications: | 2,374 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ZIPAN-25 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ZIPAN-25
US Patents and Regulatory Information for ZIPAN-25
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Altana | ZIPAN-25 | promethazine hydrochloride | INJECTABLE;INJECTION | 083997-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |